Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.91% Nasdaq Up0.87%

Cytori Therapeutics, Inc. (CYTX)

-NasdaqGM

2.33 Up 0.01(0.43%) 4:00PM EDT

Add to Portfolio
ProfileGet Profile for:
Cytori Therapeutics, Inc.
3020 Callan Road
San Diego, CA 92121
United States - Map
Phone: 858-458-0900
Fax: 858-458-0994
Website: http://www.cytori.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:127

Business Summary 

Cytori Therapeutics, Inc., a cell therapy company, engages in developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular diseases, burns, and other soft tissue injuries. It primarily provides the Celution System, which automates the process of digesting fat tissue, releasing the ADRCs. It also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; StemSource 900/MB, a research laboratory equipment; and Puregraft system that is designed to streamline the fat graft preparation process by selectively washing and filtering the tissue to remove contaminants in a closed and sterile field, as well as a range of ancillary products designed to optimize tissue harvest and graft delivery. Its products also include Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, as well as soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury. The company markets its systems, instrumentations, and consumables directly, as well as through a network of distributors to hospitals, plastic surgery clinics, tissue banks, and stem cell banking companies, as well as researchers performing investigator-initiated and funded studies worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Cytori Therapeutics, Inc.

Corporate Governance 
Cytori Therapeutics, Inc.’s ISS Governance QuickScore as of Jun 1, 2013 is 4. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Christopher J. Calhoun , 47
Co-Founder, Chief Exec. Officer, Vice Chairman and Member of Exec. Committee
577.00K187.00K
Dr. Marc H. Hedrick M.D., 50
Pres and Director
483.00K0.00
Mr. Mark E. Saad , 43
Chief Financial Officer
454.00K0.00
Mr. Clyde W. Shores , 53
Exec. VP of Marketing & Sales
439.00K0.00
Mr. Seijiro N. Shirahama , 59
Pres of Asia Pacific
537.00K0.00
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders